Platelets
67.9%lower recorded waste cost
Patient blood management across a multi-hospital health system: reducing blood-product waste through data visibility, inventory redesign, and shared clinical governance.
Actual fiscal-year totals. Recorded waste cost in US dollars, with a shared scale starting at zero.
67.9%lower recorded waste cost
54.3%lower recorded waste cost
$382,945lower annual recorded waste value across all blood products
843 to 248platelet units wasted, a 70.6% reduction
Gross waste valuation, not net savings. FY2024 includes one month after my departure from the leadership role. See timing, sources, and attribution.
Implemented clinical systems improvement
Medical Director of Transfusion Services; Transfusion Committee co-chair; physician lead for blood-product stewardship
Platelets accounted for most of the system’s blood-product waste. Their short shelf life and high cost made matching inventory to variable demand especially important across multiple hospitals.
In a previous health-system role, I served as Medical Director of Transfusion Services and Transfusion Committee co-chair. I helped lead a coordinated blood-product stewardship effort with clinical, laboratory, and operational colleagues.
I built the initial waste tracker to make losses visible and support actionable review. That gave the team a common basis for decisions about inventory and daily work.
We redesigned inventory pars and product rotation, tightened expiration review, and improved the use of products approaching expiry. Supplier coordination and clinical-practice review supported the operational changes, alongside assessment of additional platelet strategies.
The work connected measurement to committee oversight, education, and implementation across the health system.
| Fiscal year | Recorded waste cost |
|---|---|
| FY2022 | $705,806 |
| FY2023 | $591,675 |
| FY2024 | $322,861 |
Total recorded blood-product waste cost declined 54.3% between FY2022 and FY2024. Platelet waste cost declined 67.9%, from $586,728 to $188,108. The accompanying fall in platelet units wasted, from 843 to 248, documents a reduction in discarded inventory as well as its recorded value.
The fiscal years in this analysis run from September through August. FY2024 includes one month after my departure from the leadership role.
Comparing September through July in FY2022 and FY2024 keeps the outcome period within my tenure. In that matched-period analysis, recorded platelet waste cost fell 66.5% and total blood-product waste cost fell 52.5%.
These are institutional results from a team effort. The before-and-after comparison does not isolate the effect of any individual intervention or establish sole attribution. The dollar figures measure the recorded value of wasted products; they do not deduct implementation costs or establish net budget savings.
Source: institutional blood-product waste records and transfusion committee reports, as summarized in the October 2026 project analysis. The final fiscal-year totals replace the partial-year estimates previously shown on this page.
Measurement made an expensive, perishable inventory problem visible enough to manage. Sustained review, clear responsibility, and changes to daily operations gave the team a way to act on what the data showed.
These projects connect clinical expertise, usable systems, and accountable decisions—the same concerns that shape my approach to clinical informatics.